Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Fish oil pills could help fight prostate cancer, new study hints

NCT ID NCT02333435

First seen Nov 20, 2025 · Last updated Jun 22, 2026 · Updated 35 times

Summary

This phase 2 trial tests whether taking omega-3 (EPA) supplements can reduce inflammation and slow cancer cell growth in men with high-risk prostate cancer who choose surgery. 130 participants will take either EPA capsules or a placebo for 14 months, starting before surgery. Researchers will measure changes in tumor growth markers and quality of life.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Centre de Recherche Clinique et Evaluative en Oncologie - Hotel Dieu de Quebec

    Québec, Quebec, G1R 3S1, Canada

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Omega-3 (EPA) dietary supplement

What this could lead to

If it works, this could point toward a simple dietary supplement to help control prostate cancer growth and improve quality of life after surgery.

What could go wrong

This is an early phase 2 trial with only 130 participants. The supplement may not show a clear benefit, and results may not apply to all prostate cancer patients.

Conditions

The condition(s) this trial relates to.

hyperplasia Inflammation prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.